Cleared by a Ghost Device

The FDA's 510(k) clearance pathway — used for roughly 80% of new medical device authorizations — allows devices to reach market by demonstrating "substantial equivalence" to a previously cleared predicate device rather than requiring independent clinical evaluation. Over successive generations, devices accumulate significant changes in technology, materials, and intended use while maintaining a chain of equivalence back to predicates that may be decades old, withdrawn, or even recalled. This "predicate creep" means modern devices can bear little functional resemblance to the original safety baseline, yet they have never undergone independent clinical testing. Nearly 20% of 510(k) submissions rely on predicates more than 10 years old, and some chains trace back to the 1970s.

Approximately 3,000 to 4,000 510(k) clearances are issued annually, covering high-risk categories including surgical instruments, cardiovascular devices, and AI/ML diagnostic tools. When a device in a predicate chain fails in the field, the safety assumptions propagated through the entire chain are retroactively invalidated, yet downstream devices are not automatically recalled or re-evaluated. A Lancet Digital Health study found that more than one-third of AI/ML-based devices cleared via 510(k) originated from non-AI/ML predicates — meaning the "substantially equivalent" device used an entirely different technology.

In September 2023, the FDA issued three draft guidances to modernize the 510(k) program — the most significant proposed changes in decades — covering predicate selection best practices, clinical data requirements, and evidentiary expectations for implantable devices. However, these remain non-binding draft guidance and do not address the fundamental structural limitation: the 510(k) pathway is designed for incremental change, not for assessing whether cumulative changes have crossed a safety threshold. The FDA has recommended that manufacturers use the "most recent, well-characterized predicate" rather than the oldest available, but this is a suggestion, not a requirement. Devices subject to Class I recalls (the most serious category) can still serve as predicates for new submissions, propagating the safety assumptions of a recalled device into new products. No mechanism exists to evaluate cumulative technological drift across a predicate chain.

A computable "predicate distance" metric — quantifying how far a proposed device has drifted from its oldest predicate in technology, materials, and intended use — could flag submissions where cumulative change exceeds a meaningful threshold. This would require a structured, machine-readable representation of device characteristics at each step in the predicate chain, combined with a decision rule for when clinical data should be required. Adjacent models exist in software dependency tracking and version control systems.

A student team could build a network analysis tool that maps publicly available 510(k) predicate chains from the FDA database, calculates chain length and age, and identifies high-risk chains (those involving recalled predicates, technology-class changes, or extreme predicate age). A more ambitious team could prototype a "predicate distance" scoring algorithm using device classification codes, product codes, and summary documents. Relevant skills include data science, network analysis, regulatory science, and health informatics.